Gastroenterology News

Circulating tumor DNA did not successfully predict whether patients with resected stage II colon cancer would benefit from adjuvant chemotherapy, according to findings presented at ASCO Gastrointestinal Cancers Symposium.

Circulating tumor DNA-based detection of molecular residual disease appeared to be highly prognostic of patient outcomes, according to data presented at ASCO Gastrointestinal Cancers Symposium.

Patients with autoimmune disease demonstrate a 30% higher risk for perinatal depression, while those with perinatal depression have a 30% higher risk for subsequent autoimmune disease, according to data published in Molecular Psychiatry.

Topline data from the phase 2b FASCINATE-2 trial showed “statistically significant improvement” for denifanstat in biopsy-confirmed nonalcoholic steatohepatitis with stage 2 or stage 3 fibrosis at 52 weeks, Sagimet Biosciences announced.

Health care professionals who experienced recent weight loss had a significantly higher risk for a cancer diagnosis during the subsequent 12 months, results of a prospective cohort analysis revealed.

An association between moderate to severe atopic dermatitis and inflammatory bowel disease suggests a multidisciplinary approach to AD may be necessary, according to a study.

Adding radioligand therapy to first-line treatment of grade 2 or grade 3 gastroenteropancreatic neuroendocrine tumors conferred a significant reduction in risk for disease progression or death, results of a randomized study showed.

The FDA’s approval of Zymfentra in fall 2023 offers patients the “flexibility” of a subcutaneous therapy option for moderately to severely active ulcerative colitis and Crohn’s disease, Stephen B. Hanauer, MD, told Healio in an interview.

The FDA has granted breakthrough device designation to Amadix’s PreveCol, a blood test for early detection of colorectal cancer, intended to screen adults aged 45 years or older without apparent symptoms, according to a company release.

Screening for liver fibrosis was associated with improved self-reported alcohol consumption, diet, exercise and weight after 6 months among patients at risk for liver disease, with lifestyle changes persisting through 2 years.